The management of varicella‐zoster virus exposure and infection in pregnancy and the newborn period

  title={The management of varicella‐zoster virus exposure and infection in pregnancy and the newborn period},
  author={Anne‐Marle Heuchan and David Isaacs},
  journal={Medical Journal of Australia},
Zoster immunoglobulin (ZIG) should be offered to pregnant, varicella‐seronegative women with significant. exposure to varicella‐zoster virus (VZV) (chickenpox) infection. Oral aciclovir prophylaxis should be considered for susceptible pregnant women exposed to VZV who did not receive ZIG or have risk factors for severe disease. Intravenous aciclovir should be given to pregnant women who develop complicated varicella at any stage of pregnancy. Counselling on the risk of congenital varicella… 
Microbiology laboratory and the management of mother-child varicella-zoster virus infection.
A Microbiology laboratory can help in the diagnosis and management of mother-child infection at four main times: when a pregnant woman has been exposed to varicella or herpes zoster, a prompt search for specific antibodies can determine whether she is susceptible to, or protected against infection.
Preventie van neonatale infectie na peripartale blootstelling aan varicella
VZIG given very soon after exposure and combined with a delayed administration of aciclovir 7 days later, is possibly an adjunctive approach for the prevention of transplacentally transmitted neonatal infection, as well as for postnatal exposure in high-risk preterm or VLBW-infants.
Effectiveness of oral aciclovir in preventing maternal chickenpox: A comparison with VZIG
Findings support the use of oral aciclovir as first-line prophylaxis in pregnant women exposed at 20+ weeks, (and possibly second-line <20 weeks) as they suggest its effectiveness at preventing maternal chickenpox is either better or equal to VZIG.
Varicella Exposure in Neonatal Intensive Care Unit in a Low Resource Country: Successful Prophylaxis with Intravenous Immunoglobulins
A retrospective descriptive study to review the outcomes of two separate incidents of varicella-zoster exposure and the prophylactic use of IVIG in the neonatal intensive care unit in Jordan indicated that IVIG was an effective prophyllactic therapy for neonates post variceella virus exposure.
Fetal varicella – diagnosis, management, and outcome
Fetal varicella syndrome (FVS) is due to transplacental infection by the Varicella zoster virus following maternal infection, and damage results from in utero zoster following primary fetal infection.
Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus
The general information and healthcare-associated transmission of VZV is reviewed and the recommendations for the pre- and post-exposure management of HCWs and patients, in hospital settings are summarized.
Congenital varicella syndrome: A systematic review
  • K. Ahn, Yun-Jung Park, H. Kim
  • Medicine
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • 2016
Treatment for varicella zoster immunoglobulin treatment, irrespective of gestational age, should be considered in addition to antiviral drugs for women who have been exposed to or infected with virus.
Varicella zoster virus: review of its management.
  • M. Mustafa, P. Arduino, S. Porter
  • Medicine, Biology
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • 2009
The aim of the present report was to critically examine the published literature to evaluate advantages and limitations of therapy of VZV infection in both immunocompetent and Immunocompromised patients.
Managing varicella zoster infection in pregnancy.
Varicella zoster virus (VZV) infection can be serious for pregnant women and their babies, although it is rare, and preventable by preconception vaccination.
Varicella Zoster Virus Infection in Pregnancy
Though VZV infection rarely occurs during pregnancy, the disease is likely to be associated with significant complications for both mother and fetus: pregnant women are several times more likely to develop fatal varicella than non-pregnant patients, and the fetus is at high risk of congenital varICElla syndrome (CVS).


Effect of zoster immunoglobulin for varicella prophylaxis in the newborn.
The ZIG treatment clearly influenced the course of the disease for newborns at particular risk, i.e. when maternal varicella developed within 4 days before and 2 days after delivery, as well as in non-treated neonates in the defined risk group.
Chickenpox during pregnancy.
Severe primary varicella often occurs in immunocompromised patients, especially those with cell mediated immune deficiency, in whom there is also an increased risk of reactivation of latent infection, manifested by herpes zoster.
Outcome after maternal varicella infection in the first 20 weeks of pregnancy.
The absolute risk of embryopathy after maternal varicella infection in the first 20 weeks of pregnancy is about 2 percent, which is similar to that of other prospective studies.
Prevention of varicella by zoster immune globulin.
Zoster immune globulin (ZIG) was found to prevent varicella if a 2-ml dose was given to susceptible children within 72 hours of household exposure, suggesting that infection had been prevented rather than modified.
Postexposure prophylaxis of varicella in family contact by oral acyclovir.
Varicella can be prevented or modified by administration of oral ACV late in the incubation period, and in some cases, varicella-zoster virus DNA was detected by polymerase chain reaction amplification in peripheral blood mononuclear cells from blood drawn approximately 14 days after exposure.
Congenital and neonatal varicella.
Use of acyclovir for varicella pneumonia during pregnancy.
Intravenous acyclovir may reduce maternal morbidity and mortality associated with varicella pneumonia occurring during pregnancy, and appears to be safe for the developing fetus when given during the latter trimesters.
Oral acyclovir prophylaxis of varicella after intimate contact.
Oral ACV administration to healthy susceptible subjects at the beginning of secondary viremia in the late incubation period (9 days after exposure) can effectively prevent or modify clinical varicella.